RPRD1B and acute myeloid leukemia: demonstrated that small-molecule inhibitors targeting the IGF2BP family [e.g., Chemical Wnt Inhibitor 1-2 (CWI1-2)] could competitively bind to KH domains to disrupt m6A-dependent functions, showing remarkable efficacy in acute myeloid leukemia models (3).